AL001 — Topline data
Q4 2026
In March 2026, we announced the initiation of the Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with BD and expect to report topline data in the fourth quarter of 2026.Source filing
ALZN biotech catalysts & pipeline
ALZAMEND NEURO INC · Data as of 2026-10-25